NeoStem Announces Definitive Agreement to Acquire California Stem Cell, Inc.|
NeoStem, Inc. announced that it has entered into a definitive agreement to acquire California Stem Cell, Inc. As a result of this acquisition, NeoStem plans to initiate a pivotal Phase III trial of Melapuldencel-T, an autologous melanoma initiating (stem) cell immune based therapy intended to eliminate the tumor cells capable of causing disease recurrence. [NeoStem, Inc.]
Medigene Receives New US Patent for TCR-Modified T Cell Immunotherapy
Medigene AG announced that the US Patent Office has issued patent No. 8,697,854 “High affinity T cell receptor and use thereof”, relating to T-cell receptors against the tumor associated antigen tyrosinase. The patent has a term until 2030 and is licensed exclusively to Medigene’s wholly owned subsidiary Trianta Immunotherapies GmbH by Helmholtz Zentrum München. [Medigene AG]
Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy®) in Advanced Melanoma
Peregrine Pharmaceuticals, Inc. announced the opening of an investigator-sponsored trial of its investigational immunotherapy bavituximab in combination with Bristol-Myers Squibb’s ipilimumab (Yervoy®), for the treatment of advanced melanoma. [Peregrine Pharmaceuticals, Inc.]
Bavarian Nordic Announces First Patient Treated in a Phase II Study Evaluating Its Immunotherapy Candidate CV-301 in Bladder Cancer
Bavarian Nordic A/S announced the first patient has now been treated in a randomized, prospective Phase II study of its active immunotherapy candidate CV-301 in bladder cancer. [Bavarian Nordic A/S]
Have we missed an important article or publication in Human Immunology News?
Click here to submit!
Comments or Suggestions? Submit your feedback here.